PDF herunterladen
CC BY 4.0 · TH Open 2021; 05(03): e449-e460
DOI: 10.1055/s-0041-1732343
Original Article

Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist

Ohad S. Bentur 
1   Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, New York, United States
,
Jihong Li
1   Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, New York, United States
,
Caroline S. Jiang
2   The Rockefeller University Hospital, New York, New York, United States
,
Linda H. Martin
3   The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States
,
Dean J. Kereiakes
3   The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States
,
Barry S. Coller
1   Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, New York, United States
› Institutsangaben Funding B.S.C is supported by grant 19278 from the National Heart, Lung and Blood Institute and funds from Stony Brook University. B.S.C and O.S.B are supported by grant UL1 TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health. The RUC-4 Phase I study was funded by CeleCor Therapeutics. CeleCor Therapeutics supplied RUC-4, the VerifyNow assay instrument and the cartridges and tubes used in this study.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction Prehospital therapy of ST-elevation myocardial infarction (STEMI) with αIIbβ3 antagonists improves clinical outcomes, but they are difficult to use in prehospital settings. RUC-4 is a novel αIIbβ3 antagonist being developed for prehospital therapy of STEMI that rapidly achieves high-grade platelet inhibition after subcutaneous administration. Standard light transmission aggregometry (LTA) is difficult to perform during STEMI, so we applied VerifyNow (VN) assays to assess the pharmacodynamics of RUC-4 relative to aspirin and ticagrelor.

Methods Blood from healthy volunteers was anticoagulated with phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK) or sodium citrate, treated in vitro with RUC-4, aspirin, and/or ticagrelor, and tested with the VN ADP + PGE1, iso-TRAP, and base channel (high concentration iso-TRAP + PAR-4 agonist) assays. The results were correlated with both ADP (20 µM)-induced LTA and flow cytometry measurement of receptor occupancy and data from individuals treated in vivo with RUC-4.

Results RUC-4 inhibited all three VN assays, aspirin did not affect the assays, and ticagrelor markedly inhibited the ADP + PGE1 assay, slightly inhibited the iso-TRAP assay, and did not inhibit the base channel assay. RUC-4's antiplatelet effects were potentiated in citrate compared with PPACK. Cut-off values were determined to correlate the results of the VN iso-TRAP and base channel assays with 80% inhibition of LTA.

Conclusion The VN assays can differentiate the early potent anti-αIIbβ3 effects of RUC-4 from delayed effects of P2Y12 antagonists in the presence of aspirin. These pharmacodynamic assays can help guide the clinical development of RUC-4 and potentially be used to monitor RUC-4's effects in clinical practice.

Keywords

STEMI - platelet aggregation inhibitors - point-of-care testing - platelet glycoprotein GPIIb-IIIa complex - acute myocardial infarction

Author Contributions

O. S. Bentur contributed concept/design, designed, and conducted the in vitro experiments, analyzed the data, drafted the article, and critically revised the article. J. Li designed and provided training on the PAC1 binding assay. C. S. Jiang analyzed and interpreted the data. L. H. Martin participated in the planning and carrying out of the phase I study. D. J. Kereiakes was the principal investigator of the RUC-4 phase I study and critically reviewed the article. B. S. Coller conceived and oversaw the project, drafted the article, critically revised the article, and approved the article.


Supplementary Material



Publikationsverlauf

Eingereicht: 28. Januar 2021

Angenommen: 16. Juni 2021

Artikel online veröffentlicht:
28. September 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Collet J-P, Thiele H, Barbato E, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J 2021; 42 (14) 1289-1367
    CrossrefPubMedGoogle Scholar
  • 2 Ibanez B, James S, Agewall S. et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 3 Silvain J, Collet JP, Nagaswami C. et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57 (12) 1359-1367
    CrossrefPubMedGoogle Scholar
  • 4 Montalescot G, van 't Hof AW, Lapostolle F. et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedGoogle Scholar
  • 5 Bellemain-Appaix A, O'Connor SA, Silvain J. et al; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308 (23) 2507-2516
    CrossrefPubMedGoogle Scholar
  • 6 Zeymer U, Arntz HR, Mark B. et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101 (04) 305-312
    CrossrefPubMedGoogle Scholar
  • 7 Parodi G, Xanthopoulou I, Bellandi B. et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 2015; 65 (05) 511-512
    CrossrefPubMedGoogle Scholar
  • 8 Teng R. Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update. Clin Pharmacokinet 2015; 54 (11) 1125-1138
    CrossrefPubMedGoogle Scholar
  • 9 Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010; 70 (01) 65-77
    CrossrefPubMedGoogle Scholar
  • 10 Tavenier AH, Hermanides RS, Fabris E, Angiolillo DJ, van 't Hof AWJ. Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI. Int J Cardiol 2021; 328: 40-45
    CrossrefPubMedGoogle Scholar
  • 11 De Luca G, Van't Hof AW, Gibson CM. et al; EGYPT cooperation. Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation). Am J Cardiol 2015; 115 (06) 711-715
    CrossrefPubMedGoogle Scholar
  • 12 Hassan AKM, Liem SS, van der Kley F. et al. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv 2009; 74 (02) 335-343
    PubMedGoogle Scholar
  • 13 Herrmann HC, Lu J, Brodie BR. et al; FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009; 2 (10) 917-924
    CrossrefPubMedGoogle Scholar
  • 14 Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 2007; 49 (14) 1517-1524
    CrossrefPubMedGoogle Scholar
  • 15 Van't Hof AW, Ten Berg J, Heestermans T. et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372 (9638): 537-546
    CrossrefPubMedGoogle Scholar
  • 16 Rakowski T, Zalewski J, Legutko J. et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J 2007; 153 (03) 360-365
    CrossrefPubMedGoogle Scholar
  • 17 Xu Q, Yin J, Si LY. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI. Int J Cardiol 2013; 162 (03) 210-219
    CrossrefPubMedGoogle Scholar
  • 18 De Luca G, Bellandi F, Huber K. et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 2011; 9 (12) 2361-2370
    CrossrefPubMedGoogle Scholar
  • 19 Steinhubl SR, Talley JD, Braden GA. et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103 (21) 2572-2578
    CrossrefPubMedGoogle Scholar
  • 20 Bates ER, Jacobs AK. Time to treatment in patients with STEMI. N Engl J Med 2013; 369 (10) 889-892
    CrossrefPubMedGoogle Scholar
  • 21 Zhu J, Choi W-S, McCoy JG. et al. Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg2+ binding to the MIDAS. Sci Transl Med 2012; 4 (125) 125ra32
    PubMedGoogle Scholar
  • 22 Li J, Vootukuri S, Shang Y. et al. RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial in farction. Arterioscler Thromb Vasc Biol 2014; 34 (10) 2321-2329
    CrossrefPubMedGoogle Scholar
  • 23 Blue R, Murcia M, Karan C, Jirousková M, Coller BS. Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. Blood 2008; 111 (03) 1248-1256
    CrossrefPubMedGoogle Scholar
  • 24 Vootukuri S, Li J, Nedelman M. et al. Preclinical studies of RUC-4, a novel platelet αIIbβ3 antagonist, in non-human primates and with human platelets. J Clin Transl Sci 2019; 3 (2-3): 65-74
    CrossrefPubMedGoogle Scholar
  • 25 Kereiakes DJ, Henry TD, DeMaria AN. et al. First human use of RUC-4: A nonactivating second-generation small-molecule platelet glycoprotein IIb/IIIa (Integrin αIIbβ3) inhibitor designed for subcutaneous point-of-care treatment of ST-Segment-Elevation myocardial infarction. J Am Heart Assoc 2020; 9 (17) e016552
    CrossrefPubMedGoogle Scholar
  • 26 Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2002; 15 (01) 45-60
    CrossrefPubMedGoogle Scholar
  • 27 Saucedo JF, Lui HK, Garza L, Guerra GJ, Jacoski MV, Jennings LK. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. J Thromb Thrombolysis 2004; 18 (02) 67-74
    CrossrefPubMedGoogle Scholar
  • 28 Gilchrist IC, O'Shea JC, Kosoglou T. et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001; 104 (04) 406-411
    CrossrefPubMedGoogle Scholar
  • 29 Tardiff BE, Jennings LK, Harrington RA. et al; PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001; 104 (04) 399-405
    CrossrefPubMedGoogle Scholar
  • 30 ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356 (9247): 2037-2044
    CrossrefPubMedGoogle Scholar
  • 31 Steinhubl SR, Kottke-Marchant K, Moliterno DJ. et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999; 100 (19) 1977-1982
    CrossrefPubMedGoogle Scholar
  • 32 Smith JW, Steinhubl SR, Lincoff AM. et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99 (05) 620-625
    CrossrefPubMedGoogle Scholar
  • 33 van Werkum JW, Harmsze AM, Elsenberg EHAM, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008; 19 (07) 479-488
    CrossrefPubMedGoogle Scholar
  • 34 FDA 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY K141427. Accessed May 24, 2021. https://www.accessdata.fda.gov/cdrh_docs/reviews/K141427.pdf
    PubMedGoogle Scholar
  • 35 Instrumentation Laboratory. VerifyNow PRUTest Platelet Reactivity Test Instructions For use. Accessed May 24, 2021. https://www.instrumentationlaboratory.com/
    PubMedGoogle Scholar
  • 36 Instrumentation Laboratory. VerifyNow P2Y12 Platelet Reactivity Test (OUS only) Instruction For use. Accessed May 24, 2021. https://www.instrumentationlaboratory.com/
    PubMedGoogle Scholar
  • 37 Coller BS, Springer KT, Scudder LE, Kutok JL, Ceruso M, Prestwich GD. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem 1993; 268 (28) 20741-20743
    CrossrefPubMedGoogle Scholar
  • 38 Jakubowski JA, Zhou C, Egan B. et al. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism. Platelets 2011; 22 (08) 619-625
    CrossrefPubMedGoogle Scholar
  • 39 Cattaneo M, Cerletti C, Harrison P. et al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost 2013; 11: 1183-1189
    CrossrefPubMedGoogle Scholar
  • 40 Kereiakes DJ, Lorenz T, Young JJ. et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 2001; 12 (02) 123-127
    CrossrefPubMedGoogle Scholar
  • 41 Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260 (20) 11107-11114
    CrossrefPubMedGoogle Scholar
  • 42 Gerrits AJ, Jakubowski JA, Sugidachi A, Michelson AD, Frelinger III AL. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost 2017; 15 (05) 858-867
    CrossrefPubMedGoogle Scholar
  • 43 Varenhorst C, James S, Erlinge D. et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157 (03) 562.e1-562.e9
    CrossrefPubMedGoogle Scholar
  • 44 Pendyala LK, Loh JP, Lhermusier T. et al. Does baseline hematocrit influence the assays of on-treatment platelet reactivity to clopidogrel?. Am Heart J 2014; 168 (04) 545-551
    CrossrefPubMedGoogle Scholar
  • 45 Kim YG, Suh JW, Park JJ. et al. Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry. PLoS One 2014; 9 (11) e114053
    CrossrefPubMedGoogle Scholar
  • 46 Janssen PWA, Bergmeijer TO, Godschalk TC. et al. The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions. J Thromb Haemost 2017; 15 (04) 618-623
    CrossrefPubMedGoogle Scholar
  • 47 Toma C, Zahr F, Moguilanski D. et al. Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. Am J Cardiol 2012; 109 (08) 1148-1153
    CrossrefPubMedGoogle Scholar
  • 48 Choi SY, Kim MH. Comparison of factors affecting platelet reactivity in various platelet function tests. Platelets 2019; 30 (05) 631-636
    CrossrefPubMedGoogle Scholar
  • 49 Elsenberg EHAM, van Werkum JW, van de Wal RMA. et al. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102 (04) 719-727
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 50 Kakouros N, Kickler TS, Laws KM, Rade JJ. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost 2013; 11 (10) 1814-1822
    CrossrefPubMedGoogle Scholar
  • 51 Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27 (09) 1038-1047
    CrossrefPubMedGoogle Scholar
  • 52 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50 (19) 1852-1856
    CrossrefPubMedGoogle Scholar
  • 53 Bor WL, Zheng KL, Tavenier AH. et al. Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction. EuroIntervention 2021; 17: 401-410
    CrossrefPubMedGoogle Scholar